Cost-Effectiveness of Mepolizumab Versus Omalizumab as an Adjunct Therapy in Patients with Uncontrolled Allergic Asthma

May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.1593
https://www.valueinhealthjournal.com/article/S1098-3015(18)31899-0/fulltext
Section Title :
Section Order : 820
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31899-0&doi=10.1016/j.jval.2018.04.1593
HEOR Topics :
Tags :
Regions :